Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-115 with or without APG-2575 in relapsed/refractory T-PLL and NHL
NCT04496349Phase 2Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jul 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alrizomadlin in T-cell prolymphocytic leukemia (T-PLL), non-Hodgkin lymphoma (NHL), sponsored by Ascentage Pharma. Started Jul 2021; status: recruiting.
02
Drugs
alrizomadlin
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04496349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04496349.